At this week's FDA meeting on PAT and QbD, someone in the audience asked CDER Deputy Director Keith Webber, who had spoken about PAT, QbD, process validation (old vs. new) and real time release vs. end of line testing, whether FDA would ever require PAT.
Last week, Gawayne Mahboubian-Jones, one of the key thought leaders of the pharmaceutical PAT movement, left a position at Optimal Industrial Automation, whose SynTQ software is finding more users in life sciences, to join Philip Morris International as Program Manager, Excellence in Science and Design.
This week, the FDA will lose its most eloquent advocate for process analytical technologies (PAT): Ali Afnan, senior staff fellow at CDER's OPS. who leaves the Agency this Friday to pursue a career in independent consulting.
Ever get stuck behind a loud bore on an airplane? I had that misfortune last week. Eventually tuned him out, but couldn’t help but pity his quiet seat-mate, who didn’t know a peptide from a Pepsi, as he got sucked deeper and deeper into a one-sided verbal black hole,...
Raman spectroscopy, particularly hand-held Raman, is gaining favor as a pharmaceutical QC tool, given its convenience, speed and accuracy. A number of presentations at USP’s annual science meeting in Toronto discussed how hand-held Raman is being successfully used as part of pharmaceutical anticounterfeiting toolkits.
At the USP science meeting in Toronto, I met Janeen Skutnik of Pfizer, currently chair of IPEC Americas, and former IPEC chair, Colorcon's David Schonecker. (Also met incoming chair, William Dale Carter of JM Huber, who will start his new role next year).
FDA Commissioner Margaret Hamburg, whose speech on enforcement objectives and public health was just videocast live by the FDLI., appears to be the kind of leader this Agency has needed for a long time, one who communicates equally effectively to the public, politicians, industry and to colleagues within the Agency.